LifeStance Health Group, Inc. — Form 8-K Summary
Business context and reporting period
LifeStance Health Group, Inc. filed a Current Report on Form 8-K dated November 8, 2023, under Item 2.02 and Item 7.01. The filing relates to the Company’s results of operations for the third quarter ended September 30, 2023.
Financial results and key metrics
The filing states that LifeStance issued a press release announcing its third-quarter 2023 results and furnished a supplemental slide presentation. The provided filing text does not include the underlying press release or presentation and therefore does not provide clear values for revenue, profit or loss, cash flow, margins, debt, liquidity, operating metrics, or other financial measures.
Material changes versus the prior comparable period
The filing text does not provide sufficient financial data to assess changes versus the third quarter of 2022 or any other comparable period.
Guidance, outlook, risks, and unusual items
The filing text does not include guidance, outlook commentary, risk disclosures, contingencies, or unusual items. These matters may be discussed in Exhibits 99.1 and 99.2, which were furnished with the filing but are not included in the provided source text.
Information furnished under Items 2.02 and 7.01, including Exhibits 99.1 and 99.2, is not deemed filed for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other SEC filings except by specific reference.
Important facts for investors to verify
- Review Exhibit 99.1 for the complete third-quarter 2023 earnings release and reported financial results.
- Review Exhibit 99.2 for supplemental operating metrics, management commentary, guidance, and outlook.
- Verify revenue, profitability, cash flow, liquidity, debt, margins, patient or provider metrics, and year-over-year comparisons directly against the exhibits.
- Note that the filing identifies LifeStance’s common stock as trading under the symbol LFST on Nasdaq.